These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 12132492)

  • 21. A comparison of the AVID and DAVID trials of implantable defibrillators.
    Sharma A; Epstein AE; Herre JM; Klein RC; Platia EV; Wilkoff B; Ledingham RB; Greene HL; Hallstrom AP;
    Am J Cardiol; 2005 Jun; 95(12):1431-5. PubMed ID: 15950565
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Amiodarone: clinical trials.
    Naccarelli GV; Wolbrette DL; Patel HM; Luck JC
    Curr Opin Cardiol; 2000 Jan; 15(1):64-72. PubMed ID: 10666663
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factors influencing appropriate firing of the implanted defibrillator for ventricular tachycardia/fibrillation: findings from the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II).
    Singh JP; Hall WJ; McNitt S; Wang H; Daubert JP; Zareba W; Ruskin JN; Moss AJ;
    J Am Coll Cardiol; 2005 Nov; 46(9):1712-20. PubMed ID: 16256874
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prophylactic implantable cardioverter defibrillator trials: MUSTT, MADIT, and beyond. Multicenter Unsustained Tachycardia Trial. Multicenter Automatic Defibrillator Implantation Trial.
    Prystowsky EN; Nisam S
    Am J Cardiol; 2000 Dec; 86(11):1214-5, A5. PubMed ID: 11090794
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The implantable cardioverter-defibrillator and hypertrophic cardiomyopathy. Experience at three centers].
    Marín F; Gimeno JR; Payá E; García-Alberola A; Pérez-Alvarez L; Fernández X; de la Morena G; Sogorb F; Castro-Beiras A; Valdés M; Martínez JG; Monserrat L
    Rev Esp Cardiol; 2006 Jun; 59(6):537-44. PubMed ID: 16790196
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Defibrillators--end of sudden cardiac death?].
    Kozák M
    Vnitr Lek; 2004 Oct; 50 Suppl 1():S63-7. PubMed ID: 15651143
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Application of the main implantable cardioverter-defibrillator trials and the 2006 Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death.
    Proclemer A; Ghidina M
    J Cardiovasc Med (Hagerstown); 2007 May; 8(5):320-3. PubMed ID: 17443096
    [No Abstract]   [Full Text] [Related]  

  • 28. Inductionless or limited shock testing is possible in most patients with implantable cardioverter- defibrillators/cardiac resynchronization therapy defibrillators: results of the multicenter ASSURE Study (Arrhythmia Single Shock Defibrillation Threshold Testing Versus Upper Limit of Vulnerability: Risk Reduction Evaluation With Implantable Cardioverter-Defibrillator Implantations).
    Day JD; Doshi RN; Belott P; Birgersdotter-Green U; Behboodikhah M; Ott P; Glatter KA; Tobias S; Frumin H; Lee BK; Merillat J; Wiener I; Wang S; Grogin H; Chun S; Patrawalla R; Crandall B; Osborn JS; Weiss JP; Lappe DL; Neuman S
    Circulation; 2007 May; 115(18):2382-9. PubMed ID: 17470697
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Subanalyses of secondary prevention implantable cardioverter-defibrillator trials: antiarrhythmics versus implantable defibrillators (AVID), Canadian Implantable Defibrillator Study (CIDS), and Cardiac Arrest Study Hamburg (CASH).
    Oseroff O; Retyk E; Bochoeyer A
    Curr Opin Cardiol; 2004 Jan; 19(1):26-30. PubMed ID: 14688631
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Are implantable cardioverter defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomyopathy?
    Ellenbogen KA; Levine JH; Berger RD; Daubert JP; Winters SL; Greenstein E; Shalaby A; Schaechter A; Subacius H; Kadish A;
    Circulation; 2006 Feb; 113(6):776-82. PubMed ID: 16461817
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of gender on arrhythmia characteristics and outcome in the Multicenter UnSustained Tachycardia Trial.
    Russo AM; Stamato NJ; Lehmann MH; Hafley GE; Lee KL; Pieper K; Buxton AE;
    J Cardiovasc Electrophysiol; 2004 Sep; 15(9):993-8. PubMed ID: 15363069
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy.
    Vieira AP; Adragão PP; Santos KR; Morgado FB; Cavaco DM; Rossi R; Abecasis M; Neves JP; Bonhosrst D; Gomes JL; Gomes RS
    Rev Port Cardiol; 2005 Mar; 24(3):407-15. PubMed ID: 15929624
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The implantable cardioverter defibrillator: technology, indications, and impact on cardiovascular survival.
    Bhatia A; Cooley R; Berger M; Blanck Z; Dhala A; Sra J; Axtell-Mcbride K; Vandervort C; Akhtar M
    Curr Probl Cardiol; 2004 Jun; 29(6):303-56. PubMed ID: 15159713
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of n-3 polyunsaturated fatty acids on malignant ventricular arrhythmias in patients with chronic heart failure and implantable cardioverter-defibrillators: A substudy of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca (GISSI-HF) trial.
    Finzi AA; Latini R; Barlera S; Rossi MG; Ruggeri A; Mezzani A; Favero C; Franzosi MG; Serra D; Lucci D; Bianchini F; Bernasconi R; Maggioni AP; Nicolosi G; Porcu M; Tognoni G; Tavazzi L; Marchioli R
    Am Heart J; 2011 Feb; 161(2):338-343.e1. PubMed ID: 21315217
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The impact of cardiac resynchronization therapy on ventricular tachycardia/fibrillation: an analysis from the combined Contak-CD and InSync-ICD studies.
    McSwain RL; Schwartz RA; DeLurgio DB; Mera FV; Langberg JJ; León AR
    J Cardiovasc Electrophysiol; 2005 Nov; 16(11):1168-71. PubMed ID: 16302899
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induction of ventricular fibrillation rather than ventricular tachycardia predicts tachyarrhythmia recurrences in patients with idiopathic dilated cardiomyopathy and implantable cardioverter defibrillator for secondary prophylaxis.
    Rolf S; Haverkamp W; Borggrefe M; Breithardt G; Bocker D
    Europace; 2009 Mar; 11(3):289-96. PubMed ID: 19095687
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Heart failure and the risk of shocks in patients with implantable cardioverter defibrillators: results from the Triggers Of Ventricular Arrhythmias (TOVA) study.
    Whang W; Mittleman MA; Rich DQ; Wang PJ; Ruskin JN; Tofler GH; Muller JE; Albert CM;
    Circulation; 2004 Mar; 109(11):1386-91. PubMed ID: 14993132
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Malignant ventricular arrhythmia in systemic sclerosis controlled with an implantable cardioverter defibrillator.
    Martinez-Taboada V; Olalla J; Blanco R; Armona J; Sueiro JF; Rodriguez-Valverde V
    J Rheumatol; 1994 Nov; 21(11):2166-7. PubMed ID: 7869331
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiarrhythmics Versus Implantable Defibrillators (AVID)--rationale, design, and methods.
    Hallstrom AP; Greene HL; Wyse DG; Zipes D; Epstein AE; Domanski MJ; Schron EB;
    Am J Cardiol; 1995 Mar; 75(7):470-5. PubMed ID: 7863991
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Wearable cardioverter-defibrillator as a bridge to implantable cardioverter-defibrillator treatment.
    Technol Eval Cent Assess Program Exec Summ; 2010 Nov; 25(2):1-5. PubMed ID: 21638938
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.